Article Details

Trials Affirm Value of Immunotherapy in Resectable NSCLC | MedPage Today

Retrieved on: 2022-08-22 22:34:59

Tags for this article:

Click the tags to see associated articles and topics

Trials Affirm Value of Immunotherapy in Resectable NSCLC | MedPage Today. View article details on hiswai:

Excerpt

So I think it affirms what we're doing in the adjuvant setting for the PD-L1 positive patients with offering them atezolizumab after adjuvant ...

Article found on: www.medpagetoday.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up